StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research note issued on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Down 0.9 %
Shares of NASDAQ EVOK opened at $5.80 on Monday. The stock has a market cap of $4.76 million, a P/E ratio of -0.36 and a beta of 0.35. The firm’s 50-day simple moving average is $4.91 and its 200 day simple moving average is $5.51. Evoke Pharma has a fifty-two week low of $3.54 and a fifty-two week high of $17.88.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%. The company had revenue of $2.55 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Articles
- Five stocks we like better than Evoke Pharma
- How to Evaluate a Stock Before Buying
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- What is a Low P/E Ratio and What Does it Tell Investors?
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- What is a Stock Market Index and How Do You Use Them?
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
